Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry

References

• Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. 1993. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr. 15:141–147.
   Google Scholar
• Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, du Bois A, Damkier P, Vach W, Brosen K, et al. 2011. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 67:693–700.
   PubMed Web of Science ®Google Scholar
• Bevan CD, Lloyd RS. 2000. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem. 72:1781–1787.
   PubMed Web of Science ®Google Scholar
• Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma WW, Wentzel B, Kessler D, Worah D, Quay SC. 2000. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res Dordr. 17:175–182.
   PubMed Web of Science ®Google Scholar
• Dongre A, Montaldo C. 2009. Kaposi's sarcoma in an HIV-positive person successfully treated with paclitaxel. Indian J Dermatol Venereol Leprol. 75:290–292.
   PubMed Web of Science ®Google Scholar
• Donyai P, Sewell GJ. 2006. Physical and chemical stability of paclitaxel infusions in different container types. J Oncol Pharm Pract. 12:211–222.
   PubMedGoogle Scholar
• Fouda MMG, Knittel D, Hippler UC, Elsner P, Schollmeyer E. 2006. Antimycotic influence of beta-cyclodextrin complexes – in vitro measurements using laser nephelometry in microtiter plates. Int J Pharm. 311:113–121.
   PubMed Web of Science ®Google Scholar
• Gogate US, Schwartz PA, Agharkar SN. 2009. Effect of unpurified Cremophor EL on the solution stability of paclitaxel. Pharm Dev Technol. 14:1–8.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 72:191–202.
   PubMed Web of Science ®Google Scholar
• Konno T, Watanabe J, Ishihara K. 2003. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res. 65A:209–214.
   Web of Science ®Google Scholar
• Kumar S, Mahdi H, Bryant C, Shah JP, Garg G, Munkarah A. 2010. Clinical trials and progress with paclitaxel in ovarian cancer. Int J Women's Health. 2:411–427.
   PubMedGoogle Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 46:3–26.
   PubMed Web of Science ®Google Scholar
• Mahida JP, Antczak C, Decarlo D, Champ KG, Francis JH, Marr B, Polans AS, Albert DM, Abramson DH, Djaballah H. 2013. A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma. PLoS One. 8:e59156.
   PubMed Web of Science ®Google Scholar
• Pan L, Ho Q, Tsutsui K, Takahashi L. 2001. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J Pharm Sci. 90:521–529.
   PubMed Web of Science ®Google Scholar
• Price KS, Castells MC. 2002. Taxol reactions. Allergy Asthma Proc. 23:205–208.
   PubMed Web of Science ®Google Scholar
• Sato T, Kamiyama Y, Kamano T, Rutkowski J, Adams Cowley R, Trump BF, Jones RT. 1985. Pathophysiology of hemorrhagic shock. A model for studying the effects of acute blood loss in the rat. Virchows Archiv B Cell Pathol Incl Mol Pathol. 48:361–375.
   PubMedGoogle Scholar
• Schmitzhuebner U, Nachbar J, Asbeck F. 1980. The determination of anti-thrombin-III, alpha-2-macroglobulin and alpha-2-antiplasmin in plasma by laser nephelometry. J Clin Chem Clin Biochem. 18:221–225.
   PubMedGoogle Scholar
• Singla AK, Garg A, Aggarwal D. 2002. Paclitaxel and its formulations. Int J Pharm. 235:179–192.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. 1998. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 9:1–17.
   PubMed Web of Science ®Google Scholar
• Surapaneni MS, D SK, Das NG. 2012. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2012:1–15.
   Google Scholar
• Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y. 2001. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol. 1:721–735.
   PubMed Web of Science ®Google Scholar
• Sznitowska M, Klunder M, Placzek M. 2008. Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. Chem Pharm Bull. 56:70–74.
   PubMed Web of Science ®Google Scholar
• Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, et al. 1993. Paclitaxel for platinum-refractory ovarian-cancer - results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 11:2405–2410.
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. 2001. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 19:125–141.
   PubMed Web of Science ®Google Scholar
• Vasantha J, Kannan G, Goud T, Palani T, Vanitha R, Anitha R, Priya J. 2011. Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. J Young Pharm. 3:322–328.
   PubMedGoogle Scholar
• Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Vanecho DA, Vonhoff DD, Leylandjones B. 1990. Hypersensitivity reactions from taxol. J Clin Oncol. 8:1263–1268.
   PubMed Web of Science ®Google Scholar